A Phase 3 interventional study of CAELYX and Topotecan HCl in Epithelial Ovarian Cancer, sponsored by Xian-Janssen Pharmaceutical Ltd.. Terminated at 7 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-23.
Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial — none open to participants now, none under way, none of them phase 3. liposomal doxorubicin · Carcinoma, Ovarian Epithelial.
Among the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial, this one is the 8th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 9th registered.
798 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 102 are open to participants now.
Browse Carcinoma, Ovarian Epithelial studies →None of the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial is open now. The open studies under Carcinoma, Ovarian Epithelial, anywhere →
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 75 Carcinoma, Ovarian Epithelial studies recruiting now, 50 (67%) set no upper age limit and 12 (16%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 2 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 45 across 585 interventional studies indexed under Carcinoma, Ovarian Epithelial.
Median enrollment 33 across the 14 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under Xian-Janssen Pharmaceutical Ltd., one of the names counted as Johnson & Johnson. Under that name alone:
Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
Johnson & Johnson has 1 study filed under Carcinoma, Ovarian Epithelial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing liposomal doxorubicin in Carcinoma, Ovarian Epithelial, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness between CAELYX and topotecan hydrochloride (HCl) in Chinese participants with recurrent epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy, who have received no more than one prior platinum-based regimen therapy.
This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), comparative bridging study (a supplemental study which performs to provide data of effectiveness, safety, and dosage to compare two study medications in a new region). The study consists of 3 phases: screening phase (30 days before administration of study medication), treatment phase, and follow up phase (every 8 weeks for tumor assessment until disease progression or death, or until the study completion, whichever is earlier and every 3 months after disease progression for overall survival and for anti-tumor therapy for a minimum of 1 year). In the treatment phase, approximately 120 eligible participants will be categorized prospectively for platinum-sensitivity (sensitive versus refractory) and bulky disease (presence versus absence). Later on participants will be randomly assigned either to experimental arm (CAELYX: administer on Day 1 of each cycle) or control arm (topotecan HCl: administer on Day 1 to Day 5 of each cycle). Treatment will continue until disease progression occurs and may continue for at least 2 cycles after confirmed complete response (disappearance of all target lesions). On average, it is expected that participants will continue treatment for approximately 3 to 6 cycles in experimental arm (CAELYX) or 4 to 8 cycles in Control arm (topotecan HCl). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, echocardiogram (or multiple gated acquisition scans), vital signs, and physical examination which will be monitored throughout the study. The total duration of the study will be approximately 23 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
Drug: CAELYX
Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
Drug: Topotecan HCl
CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
Number of Participants With Progression-free Survival Incidence at Week 24
Progression-free survival incidence was be measured as number of participants who were progression-free and alive. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Week 24
Duration of Progression-free Survival
It was calculated as the time, in weeks, from the day of randomization until documented disease progression or death due to any cause, whichever occurs first using a Kaplan-Meier curve for PFS.
Time frame: 1 year after the last dose (24 weeks) administration
Number of Participants With Response
Response rate was measured as number of participants with at least a durable response: Complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Partial response is defined as at least a 30 percentage decrease in the sum of diameters of target lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progression in disease is defined as at least a 20% increase in the sum of diameters of target lesions. Not evaluable participants were those who were not analyzed. The reference of the baseline sum of diameters of lesions was considered.
Time frame: Up to Week 24
Time to Response
It is calculated as the day of randomization to the first observation of a durable response (the first of the 2 confirmatory measurements).
Time frame: Up to Week 24
Duration of Response
It is calculated as the first observation of a durable response (the first of the 2 confirmatory measurements) to the first observation of disease progression or death due to any cause.
Time frame: Up to 1 year of last dose (Week 24) administration
Health-related Quality of Life Assessment (HQL)
Calculation of each HQL domain scale will be performed according to the scoring guidelines for each of the HQL measures. The HQL analyses will include scales measuring physical functioning, pain, nausea, fatigue, and global quality of life. Each item is measured on a scale of 0 to 3, where 0 = no impact on quality of life and 3 = extreme impact on quality of life.
Time frame: Day 1 of each cycle of study medication and Week 4 after last dose of study medication
Number of Participants With Overall Survival
Number of Participants With Overall survival were categorized as number of 1) Deaths, 2) Still alive, 3) Early termination from the study due to lost to follow up, 4) Early termination from the study due to withdraw of consent, 5) Other. Overall survival is defined as the time interval from randomization to death from any cause.
Time frame: Week 4 after the last dose of the study medication and approximately up to 1 year after the disease progression or completion of the study treatment or death, whichever is earlier
Maximum Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Time to Reach the Maximum Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Area Under the Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Apparent Terminal Elimination Half-life of Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Apparent Terminal Elimination Rate Constant of Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Systemic Clearance of Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Apparent Volume of Distribution of Plasma Concentration of CAELYX
Time frame: 0 hour, 30 minutes, 90 minutes, 2 hours, 4 hours, 8 hours, 12 hours, Day 2, Day 3, Day 5, Day 8, and Day 11 for Cycle 1 and Cycle 2
Number of Participants With Adverse Events
An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events are symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events are Symptoms causing inability to perform basic self-care functions or Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
Time frame: Up to 30 days after the last dose of study medication
| Milestone | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Started | 14 | 12 |
| Completed | 1 | 0 |
| Not completed | 13 | 12 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Lost to follow-up | 4 | 4 |
Progression-free survival incidence was be measured as number of participants who were progression-free and alive. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
| participants | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Number of Participants With Progression-free Survival Incidence at Week 24 | 6 | 2 |
It was calculated as the time, in weeks, from the day of randomization until documented disease progression or death due to any cause, whichever occurs first using a Kaplan-Meier curve for PFS.
| weeks | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Duration of Progression-free Survival | NA (8.0 to NA) | 24.6 (7.9 to 25.1) |
Response rate was measured as number of participants with at least a durable response: Complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all target lesions. Partial response is defined as at least a 30 percentage decrease in the sum of diameters of target lesions. Stable disease defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progression in disease is defined as at least a 20% increase in the sum of diameters of target lesions. Not evaluable participants were those who were not analyzed. The reference of the baseline sum of diameters of lesions was considered.
| participants | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Complete Response (CR) | 0 | 0 |
| Partial Response (PR) | 5 | 3 |
| Stable Disease (SD) | 4 | 6 |
| Progression Disease (PD) | 1 | 1 |
| Not Evaluable (NE) | 4 | 2 |
It is calculated as the day of randomization to the first observation of a durable response (the first of the 2 confirmatory measurements).
| weeks | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Time to Response | 16.0 (8.0 to 24.1) | 16.0 (6.0 to 16.1) |
It is calculated as the first observation of a durable response (the first of the 2 confirmatory measurements) to the first observation of disease progression or death due to any cause.
| weeks | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Duration of Response | NA (8.1 to NA) | 9.3 (8.6 to 10.6) |
Calculation of each HQL domain scale will be performed according to the scoring guidelines for each of the HQL measures. The HQL analyses will include scales measuring physical functioning, pain, nausea, fatigue, and global quality of life. Each item is measured on a scale of 0 to 3, where 0 = no impact on quality of life and 3 = extreme impact on quality of life.
No measurements were reported for this outcome.
Number of Participants With Overall survival were categorized as number of 1) Deaths, 2) Still alive, 3) Early termination from the study due to lost to follow up, 4) Early termination from the study due to withdraw of consent, 5) Other. Overall survival is defined as the time interval from randomization to death from any cause.
| participants | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Death | 1 | 0 |
| Still alive | 0 | 0 |
| Early termination: due to lost to follow up | 4 | 4 |
| Early termination: due to withdraw of consent | 5 | 6 |
| Other | 4 | 2 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Grade 3 (Severe) events are symptoms causing inability to perform usual social \& functional activities. Grade 4 (Life-threatening) events are Symptoms causing inability to perform basic self-care functions or Medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.
| participants | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| TEAEs | 12 | 12 |
| TESAEs | 1 | 1 |
Collected over Up to 30 days after the last dose of study medication. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAELYX | — | 1/14 (7.1%) | 12/14 (85.7%) |
| Topotecan Hydrocloride (HCl) | — | 1/12 (8.3%) | 12/12 (100%) |
| Event | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| Platelet count decreasedInvestigations | 0/14 | 1/12 |
| Pulmonary tuberculosisInfections and infestations | 1/14 | 0/12 |
| Event | CAELYX | Topotecan Hydrocloride (HCl) |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 5/14 | 11/12 |
| White blood cell count decreasedInvestigations | 6/14 | 10/12 |
| Neutrophil count decreasedInvestigations | 6/14 | 9/12 |
| VomitingGastrointestinal disorders | 5/14 | 8/12 |
| Platelet count decreasedInvestigations | 0/14 | 6/12 |
| NauseaGastrointestinal disorders | 6/14 | 5/12 |
| LeukopeniaBlood and lymphatic system disorders | 5/14 | 2/12 |
| NeutropeniaBlood and lymphatic system disorders | 5/14 | 1/12 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 5/14 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 3/14 | 0/12 |
The modified intent-to-treat population included (mITT) included all randomized participants.
| Age, Continuous(years) | CAELYX | Topotecan Hydrocloride (HCl) | Total |
|---|---|---|---|
| Mean | 56.1 ± 4.97 | 51.6 ± 8.32 | 54.0 ± 6.96 |
| Sex: Female, Male(Participants) | CAELYX | Topotecan Hydrocloride (HCl) | Total |
|---|---|---|---|
| Female | 14 | 12 | 26 |
| Male | 0 | 0 | 0 |
The record gives a start of Jun 2013, a primary completion of May 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin
Carcinoma, Ovarian Epithelial →
Xian-Janssen Pharmaceutical Ltd. →